Clinical Research Directory
Browse clinical research sites, groups, and studies.
Stereotactic Boost and Short-course Radiation Therapy for Oropharynx Cancer
Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)
Summary
This is a randomized clinical trial comparing the outcomes of short-course chemoradiation consisting in stereotactic boost to the gross tumor and de-esclalated chemoradiation to the elective neck in human papilloma associated oropharynx cancer vs. the current standard 7-week course chemoradiation.
Official title: Stereotactic Boost and SHOrt-course Radiation Therapy for HPV-associated OroPharynx Cancer Trial: A Randomized Multicentric Phase III Trial
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
360
Start Date
2020-02-23
Completion Date
2029-12
Last Updated
2025-05-18
Healthy Volunteers
No
Interventions
SABR boost and de-escalated chemoradiation
Stereotactic body radiotherapy boost to the gross tumor volume to a dose of 14 Gy in 2 fractions, followed by cisplatin-based chemoradiation to a dose of 40 Gy in 20 fractions
Standard chemoradiation
Standard Cisplatin-based chemoradiation to a dose of 70 Gy in 33 fractions
Locations (2)
London Health Sciences Center
London, Ontario, Canada
Centre Hospitalier de l'Université de Montréal
Montreal, Quebec, Canada